Centessa Pharmaceuticals plc CNTA
At closeJun 25, 2026, 4:00 PM EDT
After hours · Jun 25, 4:00 PM ET
52-week range unavailable
- YTD
- +61.94%
- 1 year
- +201.56%
- Market cap
- 6.27B
- YTD return
- +61.94%
- 1-year return
- +201.56%
- Open
- 40.50
- Previous close
- 40.50
- Day's range
- 40.50 – 40.50
- Earnings date
- Aug 11, 2026
2Y +31.70 (+360.23%)
Key statistics
- Enterprise value
- 6.21B
- PEG ratio
- 3.15
- Price / sales
- 0.00
- Price / book
- 12.76
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -60.37%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
- Strong buy1
- Buy1
- Hold5
- Sell0
- Strong sell0
Next earnings
Aug 11, 2026
Expected Aug 11, 2026. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 11, 2026 | Jun 30, 2026 | -0.40 | — | — | — |
| May 5, 2026 | Mar 31, 2026 | -0.38 | -0.52 | -0.14 | -36.84% |
| Mar 31, 2026 | Dec 31, 2025 | -0.37144 | -0.48 | -0.11 | -29.23% |
| Nov 5, 2025 | Sep 30, 2025 | -0.39 | -0.41 | -0.02 | -5.13% |
| Aug 12, 2025 | Jun 30, 2025 | -0.35 | -0.38 | -0.03 | -8.57% |
| May 14, 2025 | Mar 31, 2025 | -0.35 | -0.20 | +0.15 | +42.86% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 20, 2026 | Wells Fargo | down | Overweight | Equal-Weight |
| Apr 2, 2026 | Guggenheim | down | Buy | Neutral |
| Apr 1, 2026 | Leerink Partners | down | Outperform | Market Perform |
| Mar 31, 2026 | Wolfe Research | down | Outperform | Peer Perform |
| Mar 31, 2026 | Needham | down | Buy | Hold |
| Feb 24, 2026 | Wolfe Research | init | — | Outperform |
About Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease. Additionally, SerpinPC, an activated protein C inhibitor, is progressing through Phase IIa clinical development for the management of hemophilia A and B. Centessa's pipeline also features several emerging assets in the clinical proof-of-concept stage. These comprise LB101 (a PD-L1xCD47 LockBody) and LB201 (a PD-L1xCD3 LockBody), both engineered to selectively activate potent CD47 and CD3 effector functions while minimizing systemic side effects. Another molecule, ZF874, is a small molecule pharmacological chaperone in Phase I studies, designed to correct the misfolding of the Z variant of alpha-1-antitrypsin, thus addressing alpha-1-antitrypsin deficiency. Furthermore, MGX292, a recombinant modified BMP9 replacement protein, aims to rectify the deficient BMP9 signaling implicated in Pulmonary Arterial Hypertension. The company is also developing OX2R Agonists, which are selective orexin receptor 2 agonists (available as oral and intranasal formulations) intended to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1 by leveraging structural insights. Beyond these, Centessa is exploring further clinical proof-of-concept compounds. CBS001, an anti-LIGHT antibody, is being investigated for inflammatory and fibrotic diseases due to its preferential binding to the inflammatory membrane form of LIGHT. Lastly, CBS004 is a humanized monoclonal antibody specifically targeting BDCA2, a protein found exclusively on plasmacytoid dendritic cells, with potential utility in conditions such as systemic sclerosis, systemic lupus erythematosus, and other autoimmune disorders. Centessa Pharmaceuticals plc was established in 2020 and is headquartered in Altrincham, United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- GB
- Employees
- 129
- Website
- centessa.com
News
Global UAV Announces Proposed Acquisition of Nexus Peptide Sciences Inc. 
Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales 
7 Health Care Stocks With Whale Alerts In Today's Session 
Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development 
Are CNTA, WSR, GDOT Obtaining Fair Deals for their Shareholders? 
Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA 
38,432 Shares in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Acquired by B. Metzler seel. Sohn & Co. AG 
Here Are Monday’s Top Wall Street Analyst Research Calls: Adobe, Best Buy, Bilibili, Constellation Brands, CoreWeave, Nike, Starbucks, T-Mobile, and More 
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders? 
Shareholder Alert: The Ademi Firm investigates whether Centessa Pharmaceuticals plc is obtaining a Fair Price for Public Shareholders
Your note
Sign in to keep a note on CNTA — it syncs with the Stock Master app.